SciELO - Scientific Electronic Library Online

 
vol.6 issue17Humanized nursing care for saphenectomized patientsMonkeypox, insights into what is known author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Vive Revista de Salud

Print version ISSN 2664-3243

Abstract

MALDONADO, Paola Alexandra Cárdenas; AGUINSACA, Karina Fernanda Pucha  and  COELLO, Mariela de los Ángeles Cárdenas. Efficacy and safety of SARS-CoV-2 vaccines in patients with autoimmune rheumatologic diseases. Vive Rev. Salud [online]. 2023, vol.6, n.17, pp.547-559.  Epub May 08, 2023. ISSN 2664-3243.  https://doi.org/10.33996/revistavive.v6i17.245.

Patients with autoimmune rheumatologic diseases have a higher risk of infection by SARS-CoV-2 due to factors inherent to the disease, as well as those derived from treatment. With the development of vaccines, immunization has been prioritized in this group of patients; however, the efficacy and safety of vaccines against SARS-CoV-2 has not been studied in this population due to their exclusion in phase II-III clinical trials. Objective. to analyze the efficacy and safety of vaccines against SARS-CoV-2 in patients with autoimmune rheumatologic diseases. Methodology. A systematic review was performed, using the PRISMA statement, as search criteria were considered Portuguese, English and Spanish publications, related to the efficacy and safety of vaccines against SARS-CoV-2 during the last 6 years. The search for articles was developed in databases such as PubMed, Scopus and ScienceDirect published in English, Portuguese and Spanish published during the last 6 years to date. Results. A total of 79 articles were found, 27 in PubMed, 52 in Google Scholar; the number was reduced to 60, eliminating 19 for duplicity, 27 for article ABSTRACT, after an exhaustive analysis of the content of the information to obtain a total of 8 articles for the analysis of the study. Conclusion. The efficacy of vaccines against SARS-CoV-2 in patients with rheumatologic diseases is reduced, attributed to the use of glucocorticoids and immunosuppressive therapies in which rituximab, mycophenolate mofetil and methotrexate stand out, while safety based on adverse effects is similar to those found in the general population.

Keywords : Rheumatic diseases; Coronavirus infections; Immunogenicity, Vaccine; Vaccines.

        · abstract in Spanish | Portuguese     · text in Spanish     · Spanish ( pdf )